gsk201510296k.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending October 2015
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--
 


GlaxoSmithKline plc
 
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
 
 
In accordance with DTR 3.1.4R(1)(a) I give details of changes in the interests of the following Directors and Persons Discharging Managerial Responsibilities ('PDMR'), in the Ordinary Shares of GlaxoSmithKline plc (the "Company") arising from the grant of options over Ordinary Shares ('Shares'), at an option price of £10.13 per share, pursuant to the GlaxoSmithKline plc ShareSave Plan 2015, on 29 October 2015.
 
 
 
Director/PDMR
 
 
                                        Share options
 
Sir Andrew Witty
 
888
 
Mr R G Connor
 
888
 
Mr S Dingemans
 
266
 
Mr N Hirons
 
888
 
Mr D S Redfern
 
888
 
Mr P C Thomson
 
533
 
Dr P J T Vallance
 
888
 
Mrs V A Whyte
 
888
 
 
The Company was advised of this change on 29 October 2015.
 
 
V A Whyte
Company Secretary
 
29 October 2015
 
 

SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: October 29, 2015 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc